SEC-sourced researchBeta
SUPN
SUPERNUS PHARMACEUTICALS, INC.
Company comparison ↗
Data passport
- CIK
- 0001356576
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Oct 6, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 607,521,000.0000 | Mar 2, 2026 |
| December 2024 | 661,817,000.0000 | Mar 2, 2026 |
| December 2025 | 718,952,000.0000 | Mar 2, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 718,952,000.0000 | -38,550,000.0000 | 47,331,000.0000 | 1,452,648,000.0000 | 390,934,000.0000 | Mar 2, 2026 |
| December 2024 | 661,817,000.0000 | 73,865,000.0000 | 171,951,000.0000 | 1,368,073,000.0000 | 332,340,000.0000 | Mar 2, 2026 |
| December 2023 | 607,521,000.0000 | 1,316,000.0000 | 111,085,000.0000 | — | — | Mar 2, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $718.95M | December 2025 | Mar 2, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $661.82M | December 2024 | Mar 2, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$38.55M | December 2025 | Mar 2, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $47.33M | December 2025 | Mar 2, 2026 | 10-K |
| Total assetsAssets | $1.45B | December 2025 | Mar 2, 2026 | 10-K |
| Total liabilitiesLiabilities | $390.93M | December 2025 | Mar 2, 2026 | 10-K |